Most Popular Articles : Journal of Immunotherapy

Secondary Logo

Journal Logo

Most Popular Articles

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication

Buti, Sebastiano; Basso, Umberto; Giannarelli, Diana; More

Journal of Immunotherapy. 46(1):22-26, January 2023.

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Qin, Jim S.; Johnstone, Timothy G.; Baturevych, Alex; More

Journal of Immunotherapy. 43(4):107-120, May 2020.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

Diem, Stefan; Fässler, Mirjam; Bomze, David; More

Journal of Immunotherapy. 42(3):89-93, April 2019.

Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells

Shrestha, Bishwas; Zhang, Yongliang; Yu, Bin; More

Journal of Immunotherapy. 43(3):79-88, April 2020.

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

Fotin-Mleczek, Mariola; Duchardt, Katharina M.; Lorenz, Christina; More

Journal of Immunotherapy. 34(1):1-15, January 2011.

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

Wang, Xueyin; Sandberg, Mark L.; Martin, Aaron D.; More

Journal of Immunotherapy. 44(8):292-306, October 2021.

Cancer and Inflammation: Promise for Biologic Therapy

Demaria, Sandra; Pikarsky, Eli; Karin, Michael; More

Journal of Immunotherapy. 33(4):335-351, May 2010.

Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma

Bishop, Andrew J.; Amini, Behrang; Lin, Heather; More

Journal of Immunotherapy. 45(8):374-378, October 2022.

A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors

Guo, Mengni; Liu, Jieying; Miao, Ruoyu; More

Journal of Immunotherapy. 45(9):389-395, November/December 2022.

Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab

Lambert, Stacie L.; Zhang, Chun; Guo, Claire; More

Journal of Immunotherapy. 45(3):167-179, April 2022.

Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB

Dudal, Sherri; Hinton, Heather; Giusti, Anna M.; More

Journal of Immunotherapy. 39(7):279-289, September 2016.

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis

Lin, Chang-Ting; Su, Po-Jung; Huang, Shih-Yu; More

Journal of Immunotherapy. 45(9):407-414, November/December 2022.

Topical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia (TOPIC-3): A Nonrandomized Multicenter Study

Hendriks, Natasja; Koeneman, Margot M.; van de Sande, Anna J.M.; More

Journal of Immunotherapy. 45(3):180-186, April 2022.

The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens

Guest, Ryan D; Hawkins, Robert E; Kirillova, Natalia; More

Journal of Immunotherapy. 28(3):203-211, May-June 2005.

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

Goff, Stephanie L.; Morgan, Richard A.; Yang, James C.; More

Journal of Immunotherapy. 42(4):126-135, May 2019.

Pustular Lichenoid Eruptions Induced by Immune Checkpoint Inhibitors: Two Case Reports and a Review of the Literature

Emonet, Charlotte; Tétart, Florence; Bauvin, Olivia; More

Journal of Immunotherapy. : January 10, 2023

Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy

Oyama, Yasuhiro; Onishi, Hideya; Koga, Satoko; More

Journal of Immunotherapy. 43(4):121-133, May 2020.

Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Petrelli, Fausto; Grizzi, Giulia; Ghidini, Michele; More

Journal of Immunotherapy. 43(1):1-7, January 2020.

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Hollyman, Daniel; Stefanski, Jolanta; Przybylowski, Mark; More

Journal of Immunotherapy. 32(2):169-180, February-March 2009.

Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale

Wang, Xiuli; Naranjo, Araceli; Brown, Christine E.; More

Journal of Immunotherapy. 35(9):689-701, November-December 2012.

Chimeric Antigen Receptor–modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model

Teng, Ruidi; Zhao, Jingjing; Zhao, Yiding; More

Journal of Immunotherapy. 42(2):33-42, February/March 2019.

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, Richard A.; Chinnasamy, Nachimuthu; Abate-Daga, Daniel; More

Journal of Immunotherapy. 36(2):133-151, February-March 2013.

Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

Nishida, Sumiyuki; Morimoto, Soyoko; Oji, Yusuke; More

Journal of Immunotherapy. 45(1):56-66, January 2022.

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Nishida, Sumiyuki; Koido, Shigeo; Takeda, Yutaka; More

Journal of Immunotherapy. 37(2):105-114, February/March 2014.

Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non–Small Cell Lung Cancer After Nivolumab Therapy

Karayama, Masato; Inoue, Yusuke; Yoshimura, Katsuhiro; More

Journal of Immunotherapy. 45(2):125-131, February/March 2022.

A Clinical Development Paradigm for Cancer Vaccines and Related Biologics

Hoos, Axel; Parmiani, Giorgio; Hege, Kristen; More

Journal of Immunotherapy. 30(1):1-15, January 2007.

CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1-Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma

de Vos, Luka; Carrillo Cano, Tzaitel Maria; Zarbl, Romina; More

Journal of Immunotherapy. 45(7):324-334, September 2022.

Updated Technology to Produce Highly Immunogenic Dendritic Cell-derived Exosomes of Clinical Grade: A Critical Role of Interferon-γ

Viaud, Sophie; Ploix, Stéphanie; Lapierre, Valérie; More

Journal of Immunotherapy. 34(1):65-75, January 2011.

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

Dulos, John; Carven, Gregory J.; van Boxtel, Susan J.; More

Journal of Immunotherapy. 35(2):169-178, February-March 2012.

Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

van Zeijl, Michiel C.T.; Haanen, John B.A.G.; Wouters, Michel W.J.M.; More

Journal of Immunotherapy. 43(8):256-264, October 2020.

Blood Dendritic Cells Generated With Flt3 Ligand and CD40 Ligand Prime CD8+ T Cells Efficiently in Cancer Patients

Davis, Ian D.; Chen, Qiyuan; Morris, Leone; More

Journal of Immunotherapy. 29(5):499-511, September-October 2006.

Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non–Small Cell Lung Cancer With a PD-L1 Expression ≥50%

Metro, Giulio; Banna, Giuseppe Luigi; Signorelli, Diego; More

Journal of Immunotherapy. 43(9):299-306, November/December 2020.

Molecular and Immune Correlates of PDCD1 (PD-1), PD-L1 (CD274), and PD-L2 (PDCD1LG2) DNA Methylation in Triple Negative Breast Cancer

Ralser, Damian J.; Klümper, Niklas; Gevensleben, Heidrun; More

Journal of Immunotherapy. 44(8):319-324, October 2021.